Loading
First author of the phase 1/2 trial of India's first CAR-T therapy, which treated adults with relapsed lymphoma and leukaemia at six Indian centres.
Hasmukh Jain is a haematolymphoid medical oncologist at Tata Memorial Hospital and first author of the Lancet Haematology report of talicabtagene autoleucel (NexCAR19) in relapsed or refractory B-cell malignancies: 64 patients were enrolled across phase 1 and 2 at six tertiary centres, with an overall response rate of 73% in 51 evaluable patients and two treatment-related deaths. He runs lymphoma and CAR-T programmes at Tata Memorial and is an investigator on Indian and international lymphoma trials.
| Title | Journal | Year |
|---|---|---|
| Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study | Lancet Haematology | 2025 |
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel.
Shares Talicabtagene autoleucel, Tata Memorial Centre, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
Shares Talicabtagene autoleucel (NexCAR19) phase 1/2, ImmunoACT, Talicabtagene autoleucel, Tata Memorial Centre.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.